Wu Xiong-Zhi, Xie Guang-Ru
Department of Integrative Oncology, Tianjin Medical University Cancer Institute and Hospital, Ti-Yuan-Bei, Huan-Hu-Xi Road, Tianjin 300060, China.
Afr J Tradit Complement Altern Med. 2008 Jun 18;5(4):325-31.
Hepatocellular carcinoma is one of the most common malignant tumors worldwide. For the difficulty of the giving sufficient dose because of the poor liver function and the low sensitivity of hepatoma cells for the chemotherapeutic agents, chemotherapy adds little to overall survival of hepatocellular carcinoma patients. The induction of terminal differentiation in tumor cells represents a possible therapeutic strategy with less toxicity. Gekko sulfated polysaccharides, isoverbascoside, Ginsenoside-Rh2, Camptothecin, 9-nitro-camptothecin, tachyplesin, Matrine, tylophorine, 7-OH-4-CH(3)-coumarin and arsenic trioxide are known to have a differentiation-inducing capability on hepatocellular carcinoma in vitro and/or in vivo. Although the therapeutic effect of the differentiation-inducing agents may not be potent when compared with that of conventional chemotherapeutic agents, they have multiple therapeutic targets, low toxicity and less probability of drug resistance. More data are required on the molecular mechanisms of therapeutic effects, dose response and potential toxicities.
肝细胞癌是全球最常见的恶性肿瘤之一。由于肝功能差导致难以给予足够剂量，且肝癌细胞对化疗药物敏感性低，化疗对肝细胞癌患者的总生存期贡献不大。诱导肿瘤细胞终末分化是一种毒性较小的潜在治疗策略。壁虎硫酸多糖、异毛蕊花糖苷、人参皂苷-Rh2、喜树碱、9-硝基喜树碱、鲎素、苦参碱、娃儿藤碱、7-羟基-4-甲基香豆素和三氧化二砷已知在体外和/或体内对肝细胞癌具有诱导分化能力。尽管与传统化疗药物相比，诱导分化剂的治疗效果可能不强，但它们具有多个治疗靶点、低毒性和较低的耐药可能性。关于其治疗作用的分子机制、剂量反应和潜在毒性，还需要更多数据。
